Trials / Completed
CompletedNCT00043342
Study of Interferon Gamma-1b by Injection for the Treatment of Patients With Cystic Fibrosis
A Phase I/II Study of Interferon Gamma-1b by Subcutaneous Injection for the Treatment of Patients With Cystic Fibrosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 51 (actual)
- Sponsor
- InterMune · Industry
- Sex
- All
- Age
- 6 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this research study is to evaluate the safety, tolerability, and efficacy of Interferon gamma-1b (IFN-gamma 1b) when administered by subcutaneous injection over a period of 4 weeks to patients with mild-to-moderate cystic fibrosis. Additionally, preliminary assessments on the effects of IFN-gamma 1b on lung function and other indicators of health will be made.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | interferon gamma-1b | 100 or 200 mcg, SQ, 3x per week |
Timeline
- Start date
- 2002-04-01
- Completion
- 2003-03-01
- First posted
- 2002-08-12
- Last updated
- 2007-11-01
Source: ClinicalTrials.gov record NCT00043342. Inclusion in this directory is not an endorsement.